Menu Search
Equities

Ondine Biomedical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VF5:FRA

Ondine Biomedical Inc

Actions
  • Price (EUR)0.0815
  • Today's Change0.009 / 12.41%
  • Shares traded8.70k
  • 1 Year change-39.63%
  • Beta0.4999
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ondine Biomedical Inc. is a Canadian life sciences company. The Company specializes in light-activated antimicrobial therapies (photo disinfection) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The Company has a pipeline of investigational products, based on its proprietary photo disinfection technology, in various stages of development. The Company's nasal photo disinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave. In the United States, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials for regulatory approval. Its products beyond nasal photo disinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, serious burns, chronic wounds, central line bloodstream infections and other indications.

  • Revenue in GBP (TTM)1.19m
  • Net income in GBP-12.88m
  • Incorporated1996
  • Employees43.00
  • Location
    Ondine Biomedical Inc888-1100 Melville StVANCOUVER V6E 4A6CanadaCAN
  • Phone+1 (604) 669-0555
  • Fax+1 (604) 669-0555
  • Websitehttps://ondinebio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.